Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma, Modern Pathology, vol.32, pp.330-337, 2019. ,
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial, The Lancet Oncology, vol.19, pp.181-193, 2018. ,
Final Version of 2009 AJCC Melanoma Staging and Classification, Journal of Clinical Oncology, vol.27, pp.6199-6206, 2009. ,
Dabrafenib: First Global Approval, Drugs, vol.73, pp.1367-1376, 2013. ,
The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia, Annu Rev Pathol, vol.9, pp.239-271, 2014. ,
Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features, Am. J. Pathol, vol.157, pp.967-972, 2000. ,
KIT Gene Mutations and Copy Number in Melanoma Subtypes, Clinical Cancer Research, vol.14, pp.6821-6828, 2008. ,
Patterns of genomic evolution in advanced melanoma, Nature Communications, vol.9, 2018. ,
Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform, Melanoma Research, vol.28, pp.96-104, 2018. ,
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy, Pigment Cell Melanoma Res, vol.26, pp.845-851, 2013. ,
Decalcification can cause the failure of BRAF molecular analyses and anti-BRAFV600E VE1 immunohistochemistry, Pathology International, vol.69, pp.219-223, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02262344
Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing, PLoS ONE, vol.8, p.70826, 2013. ,
Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy, Modern Pathology, vol.28, pp.480-486, 2015. ,
BRAF and RAS mutations in human lung cancer and melanoma, Cancer Res, vol.62, pp.6997-7000, 2002. ,
, , 2013.
, Immunohistochemical Analysis of BRAFV600E Expression of Primary and Metastatic Melanoma and Comparison With Mutation Status and Melanocyte Differentiation Antigens of Metastatic Lesions, The American Journal of Surgical Pathology, vol.37, pp.413-420
, , 2017.
, Reduced H3K27me3 Expression Is Common in Nodular Melanomas of Childhood Associated With Congenital Melanocytic Nevi But Not in Proliferative Nodules, The American Journal of Surgical Pathology, vol.41, pp.396-404
Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody, Acta Neuropathologica, vol.122, pp.11-19, 2011. ,
Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in melanoma patients, Tumor Biology, vol.35, pp.5727-5733, 2014. ,
The biologic forms of malignant melanoma, Human Pathology, vol.17, pp.443-450, 1986. ,
, , 2017.
, Genomic Analysis of Pigmented Epithelioid Melanocytomas Reveals Recurrent Alterations in PRKAR1A, and, vol.41, pp.1333-1346
Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing, J Mol Diagn, vol.15, pp.94-100, 2013. ,
Heterogeneous distribution of BRAF/NRAS 53 mutations among Italian patients with advanced melanoma, Journal of Translational Medicine, vol.11, p.202, 2013. ,
Distinct Sets of Genetic Alterations in Melanoma, New England Journal of Medicine, vol.353, pp.2135-2147, 2005. ,
Somatic Activation of KIT in Distinct Subtypes of Melanoma, Journal of Clinical Oncology, vol.24, pp.4340-4346, 2006. ,
Histopathologic and mutational analysis of a case of blue nevus-like melanoma: Analysis of a case of BNLM, Journal of Cutaneous Pathology, vol.43, pp.776-780, 2016. ,
Mutations of the BRAF gene in human cancer, Nature, vol.417, pp.949-954, 2002. ,
Library preparation methods for nextgeneration sequencing: Tone down the bias, Experimental Cell Research, vol.322, pp.12-20, 2014. ,
NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing, Melanoma Res, vol.16, pp.471-478, 2006. ,
BRAF Mutations in Metastatic Malignant Melanoma: Comparison of Molecular Analysis and Immunohistochemical Expression, Applied Immunohistochemistry & Molecular Morphology, vol.22, pp.648-651, 2014. ,
BRAF V600E Protein Expression in Primary Cutaneous Malignant Melanomas and Paired Metastases, JAMA Dermatology, vol.151, p.410, 2015. ,
Giant congenital melanocytic nevus with vascular malformation and epidermal cysts associated with a somatic activating mutation in BRAF, Pigment Cell & Melanoma Research, vol.31, pp.437-441, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01613153
, , 2018.
clone VE1) est une méthode économique, spécifique et sensible pour détecter la présence d'une mutation BRAFV600E dans le mélanome, Annales de Dermatologie et de Vénéréologie, vol.145, pp.159-165 ,
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma, New England Journal of Medicine, vol.376, pp.2211-54, 2017. ,
Immunohistochemistry with a mutationspecific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma, Modern Pathology, vol.26, pp.414-420, 2013. ,
, , 2014.
, Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays, Hum. Pathol, vol.45, pp.2281-2293
SF3B1 mutations are associated with alternative splicing in uveal melanoma, Cancer Discov, vol.3, pp.1122-1129, 2013. ,
Gene of the month: BRAF, J. Clin. Pathol, vol.65, pp.986-988, 2012. ,
SF3B1 and BAP1 mutations in blue nevus-like melanoma, Mod. Pathol, vol.30, pp.928-939, 2017. ,
Intratumor and Intertumor Heterogeneity in Melanoma, Translational Oncology, vol.10, pp.956-975, 2017. ,
Frequent mutation of BAP1 in metastasizing uveal melanomas, Science, vol.330, pp.1410-1413, 2010. ,
Detection of BRAF Mutations Using a Fully Automated Platform and Comparison with High Resolution Melting, Real-Time Allele Specific Amplification, Immunohistochemistry and Next Generation Sequencing Assays, for Patients with Metastatic Melanoma, PLOS ONE, vol.11, 2016. ,
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature, vol.464, pp.431-435, 2010. ,
Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations, British Journal of Cancer, vol.109, pp.2833-2841, 2013. ,
Usefulness of Immunocytochemistry for the Detection of the BRAFV600E Mutation in Circulating Tumor Cells from Metastatic Melanoma Patients, Journal of Investigative Dermatology, vol.133, pp.1378-1381, 2013. ,
A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan: Detecting BRAF mutation in melanoma, Asia-Pacific Journal of Clinical Oncology, vol.12, pp.403-408, 2016. ,
Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations, BMC Cancer, vol.14, p.13, 2014. ,
Comparison of Next-generation Sequencing Mutation Profiling With BRAF and IDH1 Mutation-specific Immunohistochemistry, The American Journal of Surgical Pathology, vol.39, pp.454-461, 2015. ,
Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4, Oncotarget, vol.7, 2016. ,
Immunohistochemistry versus nextgeneration sequencing for the routine detection of BRAF V600E mutation in melanomas, Human Pathology, vol.45, pp.1983-1984, 2014. ,
BRAF V600E and NRAS Q61L/Q61R mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting, Histopathology, vol.69, pp.680-686, 2016. ,
BRAF V600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts, Cell Reports, vol.16, pp.263-277, 2016. ,
FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation, Clin. Cancer Res, vol.20, pp.4994-5000, 2014. ,
Multiple Congenital Melanocytic Nevi and Neurocutaneous Melanosis Are Caused by Postzygotic Mutations in Codon 61 of NRAS, Journal of Investigative Dermatology, vol.133, pp.2229-2236, 2013. ,
Melanoma in congenital melanocytic naevi, British Journal of Dermatology, vol.176, pp.1131-1143, 2017. ,
Comparative analysis of BRAF , NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma, Experimental Dermatology, vol.24, pp.70-73, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01818897
Melanoma risk in congenital melanocytic naevi: a systematic review, British Journal of Dermatology, vol.155, pp.1-8, 2006. ,
A role for immunohistochemical detection of BRAF V600E prior to BRAFinhibitor treatment of malignant melanoma, Journal of Clinical Pathology, vol.66, pp.723-725, 2013. ,
Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions, Cancer Research and Treatment, vol.50, pp.1378-1387, 2018. ,
La voie de signalisation RAS/MAPK. Cancéro Digest II, 2010. ,
, , 2014.
, Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1, Pathol. Int, vol.64, pp.601-606
A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma, British Journal of Cancer, vol.115, pp.223-227, 2016. ,
Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens, Tumor Biology, vol.36, pp.1003-1013, 2015. ,
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma, J. Clin. Oncol, vol.29, pp.1239-1246, 2011. ,
Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma, Am. J. Surg. Pathol, vol.37, pp.61-65, 2013. ,
, , 2017.
, New England Journal of Medicine, vol.377, pp.1813-1823
Utility and evaluation of immunohistochemical detection of BRAF V600E mutation in melanoma, 2017. ,
, Zhonghua Bing Li Xue Za Zhi, vol.46, pp.548-552
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebocontrolled, multicentre, The Lancet Oncology, vol.19, pp.510-520, 2018. ,
Highly Concordant Results Between Immunohistochemistry and Molecular Testing of Mutated V600E BRAF in Primary and Metastatic Melanoma, Acta Dermato Venereologica, vol.96, pp.630-634, 2016. ,
Coût du séquençage NGS à visée diagnostique en génétique somatique et constitutionnelle : estimations issues de 15 laboratoires français de génétique moléculaire des cancers, vol.65, pp.83-84, 2017. ,
Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3, Nature Genetics, vol.45, pp.933-936, 2013. ,
, Histological Diagnosis of Nevi and Melanoma, 2014.
Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi, Modern Pathology, vol.30, pp.350-356, 2017. ,
Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological Features, Journal of Investigative Dermatology, vol.138, pp.933-945, 2018. ,
Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases, Histopathology, vol.72, pp.814-825, 2018. ,
Immunohistochemical detection of V600E BRAF mutation is a useful primary screening tool for malignant melanoma, British Journal of Biomedical Science, vol.76, pp.77-82, 2019. ,
5-Hydroxymethylcytosine Expression in 58, 2016. ,
, Proliferative Nodules Arising within Congenital Nevi Allows Differentiation from Malignant Melanoma, Journal of Investigative Dermatology, vol.136, pp.2453-2461
Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma: VE1 immunostain for BRAF V600E mutant melanoma, Journal of Cutaneous Pathology, vol.41, pp.724-732, 2014. ,
High frequency of BRAF mutations in nevi, Nature Genetics, vol.33, pp.19-20, 2003. ,
, , 2015.
Spitz melanoma is a distinct subset of spitzoid melanoma, Modern Pathology, 2020. ,
Intra-and Inter-Tumoral Homogeneity of BRAF(V600E) Mutations in Melanoma Tumors, J. Invest. Dermatol, vol.135, pp.3078-3085, 2015. ,
Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas, Human Pathology, vol.44, pp.2563-2570, 2013. ,
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032, J Transl Med, vol.8, p.67, 2010. ,
Is a Single BRAF Wild-Type Test Sufficient to Exclude Melanoma Patients from Vemurafenib Therapy, Journal of Investigative Dermatology, vol.134, pp.1468-1470, 2014. ,
Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma, Pathology -Research and Practice, vol.213, pp.522-530, 2017. ,
From melanocytes to melanomas, Nat. Rev. Cancer, vol.16, pp.345-358, 2016. ,
Nevus-associated melanomas: clinicopathologic features, Am. J. Clin. Pathol, vol.142, pp.485-491, 2014. ,
Uveal Melanoma: Trends in Incidence, Treatment, and Survival, Ophthalmology, vol.118, pp.1881-1885, 2011. ,
Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1, Journal of the American Academy of Dermatology, vol.67, pp.488-491, 2012. ,
Oncogenic RAF: a brief history of time, Pigment Cell Melanoma Res, vol.23, pp.760-762, 2010. ,
Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma, Human Pathology, vol.46, pp.169-175, 2015. ,
Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis, European Journal of Cancer, vol.81, pp.106-115, 2017. ,
Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay, PLoS ONE, vol.14, 2019. ,
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi, Nature, vol.457, pp.599-602, 2009. ,
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi, Nature, vol.457, pp.599-602, 2009. ,
, Mutations in GNA11 in Uveal Melanoma, vol.363, pp.2191-2199, 2010.
, Mutations in GNA11 in Uveal Melanoma, vol.363, pp.2191-2199, 2010.
Racial differences in six major subtypes of melanoma: descriptive epidemiology, BMC Cancer, vol.16, p.691, 2016. ,
, , 2012.
, A Distinct Subset of Atypical Spitz Tumors is Characterized by BRAF Mutation and Loss of 60 BAP1 Expression, The American Journal of Surgical Pathology, vol.36, pp.818-830
Kinase fusions are frequent in Spitz tumours and spitzoid melanomas, Nat Commun, vol.5, p.3116, 2014. ,
Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation, Nucleic Acids Research, vol.35, pp.41-41, 2007. ,
Intra-and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma, PLoS ONE, vol.7, 2012. ,
Clonal BRAF Mutations in Melanocytic Nevi and Initiating Role of BRAF in Melanocytic Neoplasia, JNCI: Journal of the National Cancer Institute, vol.105, pp.917-919, 2013. ,
Ambiguous Melanocytic Tumors With Loss of 3p21, The American Journal of Surgical Pathology, vol.38, pp.1088-1095, 2014. ,
Activating MET kinase rearrangements in melanoma and Spitz tumours, Nat Commun, vol.6, p.7174, 2015. ,
NTRK3 kinase fusions in Spitz tumours, J. Pathol, vol.240, pp.282-290, 2016. ,
Combined activation of MAP kinase pathway and ?catenin signaling cause deep penetrating nevi, Nature Communications, vol.8, 2017. ,